Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.18 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (neutrophils) | 0.10 |
| chemistry Open Targets | a small-molecule pocket | 0.50 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 1,123 | 0.79 |
| pathways Reactome | 4 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 2114
Sealed predictions
- S100A12 in dopamine neurons, braak+0.30 (p 0.428) → -0.12 (p 0.768)receipt 2122
Swarm cases
receipt 2122: S100A12 in dopamine neurons, braak
- power
- full sample -0.02 (p 0.942, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.02 (p 0.935, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.00 (p 0.990, n 18). could be the mix.
- skeptic
- leave-one-out range -0.17 to +0.09, sign flips 7; without severely affected donors -0.02 (p 0.942, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for S100A12 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts